COMP <GO>
NBIX vs MRK // NET PROFIT MARGIN
Neurocrine Biosciences Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: NBIX 6
— MRK 9
▲ NET PROFIT MARGIN LEADER: MRK
LAST: $146.10 (-0.19%) • MKT CAP: $14.88B
net-margins
16.70%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
net-margins
28.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NBIX VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NBIX | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 74.80% | +21.20 | NBIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 15.70% | 20.70% | -5.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 22.8x | 15.3x | +7.50 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 5.03% | 3.42% | +1.61 | NBIX | /fcf-yield <GO> |
| Operating Margin | 21.60% | 34.30% | -12.70 | MRK | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 16.70% | 28.10% | -11.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 21.40% | 1.30% | +20.10 | NBIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.13 | 5.19 | +2.94 | NBIX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | NBIX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.60% | +0.70 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.5 | 56.9 | -1.40 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.92 | +0.21 | NBIX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.1x | 18.4x | +7.70 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $14.88B | $361.02B | -$346.14B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NBIX REV | MRK REV | NBIX GROSS % | MRK GROSS % | NBIX FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.86B | $65.01B | 98.2% | 74.8% | $748.7M | $12.36B |
| FY 2024 | $2.36B | $64.17B | 98.6% | 76.3% | $557.2M | $18.10B |
| FY 2023 | $1.89B | $60.12B | 44.0% | 44.0% | $305.0M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NBIX // BETA 1.13
MRK // BETA 0.92